Brands
Oracle layoffs affect up to 30,000 employees globally
Job cuts span US, India and more, staff cite abrupt emails, uncertainty.
MUMBAI: April began with an inbox shock and for thousands, it ended with an exit. Oracle has carried out a sweeping round of layoffs, impacting an estimated 20,000 to 30,000 employees across its global operations, even as the company continues to report strong business performance. The job cuts were communicated via emails sent early on April 1, affecting staff across multiple regions including the United States, India, Canada and parts of Latin America. The reduction spans a wide range of roles and functions, though the company has not disclosed specific criteria behind the decisions.
In the days following the layoffs, employees have taken to platforms such as LinkedIn to share their experiences, many describing the process as abrupt and unsettling. Several posts pointed to a lack of prior indication, with notifications arriving suddenly in early-morning messages.
A recurring concern has been the impact on long-tenured staff. Users reported that employees with decades of experience were among those let go, raising broader questions about job security even for seasoned professionals within large technology firms.
The layoffs have also sparked anxiety about the wider direction of the sector. As companies continue to invest heavily in automation and artificial intelligence, workforce recalibration is becoming more common often accompanied by uncertainty around future roles and skills.
For many affected employees, the immediate challenge lies in navigating career transitions in an increasingly competitive job market, with posts reflecting concerns about stability and next steps.
The development comes against a backdrop of strong financial performance at Oracle, which recently reported a 22 percent year-on-year increase in revenue, alongside continued growth in its cloud infrastructure business. The company has also been committing significant capital towards artificial intelligence and data centre expansion.
The contrast between growth and job cuts has added to the unease, underscoring a broader shift in how large technology firms balance expansion with efficiency sometimes at the cost of the very workforce that helped build that growth.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
